Cargando…
Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis
In this systematic review and meta-analysis, we sought to evaluate the prevalence of cardiac involvement in patients with COVID-19 using cardiac magnetic resonance imaging. A literature review was performed to investigate the left ventricular (LV) and right ventricular (RV) ejection fraction (EF), t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925980/ https://www.ncbi.nlm.nih.gov/pubmed/35294611 http://dx.doi.org/10.1007/s00380-022-02055-6 |
_version_ | 1784670140890087424 |
---|---|
author | Kato, Shingo Azuma, Mai Fukui, Kazuki Kodama, Sho Nakayama, Naoki Kitamura, Hideya Hagiwara, Eri Ogura, Takashi Horita, Nobuyuki Namkoong, Ho Kimura, Kazuo Tamura, Kouichi Utsunomiya, Daisuke |
author_facet | Kato, Shingo Azuma, Mai Fukui, Kazuki Kodama, Sho Nakayama, Naoki Kitamura, Hideya Hagiwara, Eri Ogura, Takashi Horita, Nobuyuki Namkoong, Ho Kimura, Kazuo Tamura, Kouichi Utsunomiya, Daisuke |
author_sort | Kato, Shingo |
collection | PubMed |
description | In this systematic review and meta-analysis, we sought to evaluate the prevalence of cardiac involvement in patients with COVID-19 using cardiac magnetic resonance imaging. A literature review was performed to investigate the left ventricular (LV) and right ventricular (RV) ejection fraction (EF), the prevalence of LV late gadolinium enhancement (LGE), pericardial enhancement, abnormality on T1 mapping, and T2 mapping/T2-weighted imaging (T2WI), and myocarditis (defined by modified Lake Louis criteria). Pooled mean differences (MD) between COVID-19 patients and controls for LVEF and RVEF were estimated using random-effects models. We included data from 10.462 patients with COVID-19, comprising 1.010 non-athletes and 9.452 athletes from 29 eligible studies. The meta-analysis showed a significant difference between COVID-19 patients and controls in terms of LVEF [MD = − 2.84, 95% confidence interval (CI) − 5.11 to − 0.56, p < 0.001] and RVEF (MD = − 2.69%, 95% CI − 4.41 to − 1.27, p < 0.001). However, in athletes, no significant difference was identified in LVEF (MD = − 0.74%, 95% CI − 2.41 to − 0.93, p = 0.39) or RVEF (MD = − 1.88%, 95% CI − 5.21 to 1.46, p = 0.27). In non-athletes, the prevalence of LV LGE abnormalities, pericardial enhancement, T1 mapping, T2 mapping/T2WI, myocarditis were 27.5% (95%CI 17.4–37.6%), 11.9% (95%CI 4.1–19.6%), 39.5% (95%CI 16.2–62.8%), 38.1% (95%CI 19.0–57.1%) and 17.6% (95%CI 6.3–28.9%), respectively. In athletes, these values were 10.8% (95%CI 2.3–19.4%), 35.4% (95%CI − 3.2 to 73.9%), 5.7% (95%CI − 2.9 to 14.2%), 1.9% (95%CI 1.1–2.7%), 0.9% (0.3–1.6%), respectively. Both LVEF and RVEF were significantly impaired in COVID-19 patients compared to controls, but not in athletes. In addition, the prevalence of myocardial involvement is not negligible in patients with COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00380-022-02055-6. |
format | Online Article Text |
id | pubmed-8925980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-89259802022-03-17 Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis Kato, Shingo Azuma, Mai Fukui, Kazuki Kodama, Sho Nakayama, Naoki Kitamura, Hideya Hagiwara, Eri Ogura, Takashi Horita, Nobuyuki Namkoong, Ho Kimura, Kazuo Tamura, Kouichi Utsunomiya, Daisuke Heart Vessels Original Article In this systematic review and meta-analysis, we sought to evaluate the prevalence of cardiac involvement in patients with COVID-19 using cardiac magnetic resonance imaging. A literature review was performed to investigate the left ventricular (LV) and right ventricular (RV) ejection fraction (EF), the prevalence of LV late gadolinium enhancement (LGE), pericardial enhancement, abnormality on T1 mapping, and T2 mapping/T2-weighted imaging (T2WI), and myocarditis (defined by modified Lake Louis criteria). Pooled mean differences (MD) between COVID-19 patients and controls for LVEF and RVEF were estimated using random-effects models. We included data from 10.462 patients with COVID-19, comprising 1.010 non-athletes and 9.452 athletes from 29 eligible studies. The meta-analysis showed a significant difference between COVID-19 patients and controls in terms of LVEF [MD = − 2.84, 95% confidence interval (CI) − 5.11 to − 0.56, p < 0.001] and RVEF (MD = − 2.69%, 95% CI − 4.41 to − 1.27, p < 0.001). However, in athletes, no significant difference was identified in LVEF (MD = − 0.74%, 95% CI − 2.41 to − 0.93, p = 0.39) or RVEF (MD = − 1.88%, 95% CI − 5.21 to 1.46, p = 0.27). In non-athletes, the prevalence of LV LGE abnormalities, pericardial enhancement, T1 mapping, T2 mapping/T2WI, myocarditis were 27.5% (95%CI 17.4–37.6%), 11.9% (95%CI 4.1–19.6%), 39.5% (95%CI 16.2–62.8%), 38.1% (95%CI 19.0–57.1%) and 17.6% (95%CI 6.3–28.9%), respectively. In athletes, these values were 10.8% (95%CI 2.3–19.4%), 35.4% (95%CI − 3.2 to 73.9%), 5.7% (95%CI − 2.9 to 14.2%), 1.9% (95%CI 1.1–2.7%), 0.9% (0.3–1.6%), respectively. Both LVEF and RVEF were significantly impaired in COVID-19 patients compared to controls, but not in athletes. In addition, the prevalence of myocardial involvement is not negligible in patients with COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00380-022-02055-6. Springer Japan 2022-03-16 2022 /pmc/articles/PMC8925980/ /pubmed/35294611 http://dx.doi.org/10.1007/s00380-022-02055-6 Text en © Springer Japan KK, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Kato, Shingo Azuma, Mai Fukui, Kazuki Kodama, Sho Nakayama, Naoki Kitamura, Hideya Hagiwara, Eri Ogura, Takashi Horita, Nobuyuki Namkoong, Ho Kimura, Kazuo Tamura, Kouichi Utsunomiya, Daisuke Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
title | Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
title_full | Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
title_fullStr | Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
title_full_unstemmed | Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
title_short | Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
title_sort | cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925980/ https://www.ncbi.nlm.nih.gov/pubmed/35294611 http://dx.doi.org/10.1007/s00380-022-02055-6 |
work_keys_str_mv | AT katoshingo cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT azumamai cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT fukuikazuki cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT kodamasho cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT nakayamanaoki cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT kitamurahideya cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT hagiwaraeri cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT oguratakashi cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT horitanobuyuki cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT namkoongho cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT kimurakazuo cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT tamurakouichi cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis AT utsunomiyadaisuke cardiacinvolvementincoronavirusdisease2019assessedbycardiacmagneticresonanceimagingametaanalysis |